Phase I Two-Dimensional Dose-Finding Study of Bortezomib in Combination with Gemcitabine/Doxorubicin in Metastatic Surgically Unresectable Urothelial Cancer or Other Solid Tumours.

Trial Profile

Phase I Two-Dimensional Dose-Finding Study of Bortezomib in Combination with Gemcitabine/Doxorubicin in Metastatic Surgically Unresectable Urothelial Cancer or Other Solid Tumours.

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 31 Mar 2017

At a glance

  • Drugs Bortezomib (Primary) ; Doxorubicin; Gemcitabine
  • Indications Urogenital cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 24 Mar 2017 Planned primary completion date changed from 1 Sep 2017 to 1 Sep 2018.
    • 22 Mar 2016 Planned primary completion date changed from 1 Sep 2016 to 1 Sep 2017 as reported by ClinicalTrials.gov.
    • 22 Mar 2015 Planned primary completion date changed from 1 Sep 2015 to 1 Sep 2016, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top